Abstract
Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy.
Objective and Conclusion: This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.
Keywords: Targeted alpha therapy, alpha emitter, actinium-225, bismuth-213, nuclide production, clinical application.
Current Radiopharmaceuticals
Title:An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Volume: 11 Issue: 3
Author(s): Alfred Morgenstern*, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki and Frank Bruchertseifer
Affiliation:
- European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe,Germany
Keywords: Targeted alpha therapy, alpha emitter, actinium-225, bismuth-213, nuclide production, clinical application.
Abstract: Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy.
Objective and Conclusion: This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.
Export Options
About this article
Cite this article as:
Morgenstern Alfred*, Apostolidis Christos, Kratochwil Clemens, Sathekge Mike, Krolicki Leszek and Bruchertseifer Frank, An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth, Current Radiopharmaceuticals 2018; 11 (3) . https://dx.doi.org/10.2174/1874471011666180502104524
DOI https://dx.doi.org/10.2174/1874471011666180502104524 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Molecular Evidence of Compound Kushen Injection Against Lung Cancer: A Network Pharmacology-Based Investigation from Western Medicine to Traditional Medicine
Anti-Cancer Agents in Medicinal Chemistry Mechanisms Underlying Beneficial Health Effects of Tea Catechins to Improve Insulin Resistance and Endothelial Dysfunction
Endocrine, Metabolic & Immune Disorders - Drug Targets Different 6-Aryl-Fulvenes Exert Anti-proliferative effects on Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Smart Biodecorated Hybrid Nanoparticles
Current Bionanotechnology (Discontinued) Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies ING Proteins as Potential Anticancer Drug Targets
Current Drug Targets Photodynamic Therapy in Melanoma - Where do we Stand?
Current Medicinal Chemistry Cytochrome P450 2W1 (CYP2W1) in Colorectal Cancers
Current Cancer Drug Targets Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets Syntheses and Preliminary Evaluation of Dual Target PET Probe [<sup>18</sup>F]-NOTA-Gly3- E (2PEG4-RGD-WH701) for PET Imaging of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Bombacaceae Between the Ethnomedical Uses and Pharmacological Evidences: A Review
The Natural Products Journal Group-sparse Modeling Drug-kinase Networks for Predicting Combinatorial Drug Sensitivity in Cancer Cells
Current Bioinformatics Rational Design and Development of Colon-Specific Prodrugs
Current Topics in Medicinal Chemistry The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology Current Phthalocyanines Delivery Systems in Photodynamic Therapy: An Updated Review
Current Medicinal Chemistry Surgical Staging for Cervical Cancer
Current Women`s Health Reviews Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Current Neuropharmacology Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology